Infosys director Ann Fudge not to seek reappointment
Infosys today said independent director Ann Fudge has conveyed her intention not to seek reappointment "owing to her busy schedule". Her term completes on June 14, 2014.
Currently, Infosys board has seven independent director and six executive directors. Infosys had recently announced the appointment of Carol M. Browner, a senior fellow at American Progress and senior counselor at Albright Stonebridge Group, as an additional director of the company.
Ann Fudge in a statement said, "Due to increasing time commitment on other boards, I have decided not to seek reappointment on the Infosys board. With the addition of new board members and a solid succession plan in place, I know the company is well-positioned for success."
Ann Fudge, who was the former chief of Young & Rubicam Brands, also serves on the board of General Electric, Novartis and Unilever.
Infosys earlier said that it has started looking for a new CEO in preparation for the retirement of S.D. Shibulal early next year, and appointed advisory firm Egon Zehnder to assist a committee in identifying external candidates. (See: Infosys CEO Shibulal says leaving behind a stronger company)
(With Agency inputs)
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.